We validated KCTD6 overexpression in clinical samples using RT-PCR, and survival analysis revealed that the overall survival time of HCC patients in the overexpression KCTD6 group was significantly worse than in the low expression group, indicating that KCTD6 overexpression may promote tumor progression in HCC. Here, KCTD6 is linked to hepatocellular carcinoma.